source
- Biotech deal activity picks up in Q2 2026, signaling recovery after summer slumpThe biotech sector experienced a sharp decline in confidence last summer, leading to a slowdown in financing and partnership activity. New data show that in the second quarter of 2026, dealmaking…
- Vertex pays second-highest M&A premium as sole bidder for CrineticsVertex Pharmaceuticals emerged as the only bidder for Crinetics Pharmaceuticals, aiming to acquire the company. The bid involved a premium that ranks as the second-highest in the biopharma sector…